---
id: 110
title: Enterococcus and VRE Management
category: organisms
subcategory: gram_positive_cocci
tags: [Enterococcus, VRE, E-faecalis, E-faecium, vancomycin-resistance]
difficulty: medium
---

## Question

How is *Enterococcus* (including VRE) treated? Use the **"Ampicillin for Faecalis, Vanc for Faecium, Daptomycin/Linezolid for VRE"** framework.

## Answer

### **Enterococcal Species:**

**Two Main Species:**
1. ***E. faecalis*** (85-90% of infections) - **More susceptible**
2. ***E. faecium*** (10-15% of infections) - **More resistant** (often VRE)

### **Treatment by Species and Resistance:**

| Organism | First-Line | Alternatives | Notes |
|----------|-----------|--------------|-------|
| ***E. faecalis*** (susceptible) | **Ampicillin 2g IV q4h** | Penicillin G (endocarditis: + gentamicin synergy) | Intrinsically resistant to cephalosporins |
| ***E. faecium*** (susceptible) | **Vancomycin 15-20 mg/kg IV q8-12h** | Linezolid, daptomycin | Ampicillin-resistant |
| **VRE** (*E. faecium*) | **Daptomycin 8-12 mg/kg IV daily** OR **linezolid 600mg IV/PO q12h** | Oritavancin (single dose), tigecycline | **NOT ampicillin or vancomycin** |

### **Key Infections:**

**Urinary Tract Infections:**
- **Cystitis (VRE):** **Nitrofurantoin 100mg PO BID** OR **fosfomycin 3g × 1**
- **Pyelonephritis/Bacteremia:** Daptomycin or linezolid

**Intra-Abdominal Infections:**
- **Empiric:** Cover enterococci if high-risk (immunocompromised, post-op, healthcare-associated)
- **VRE:** Daptomycin or linezolid

**Endocarditis:**
- ***E. faecalis*:** **Ampicillin 2g IV q4h + gentamicin 1 mg/kg IV q8h** × 4-6 weeks (synergy)
- **VRE:** **Daptomycin 10-12 mg/kg IV daily** (higher dose for endocarditis)

## Key Points

### **Intrinsic Resistances:**
- **All enterococci:**
  - **Cephalosporins** (intrinsic resistance)
  - **Aminoglycosides** (low-level, require synergy with cell wall agent)
- ***E. faecium*:** Often **ampicillin-resistant**

### **VRE Types:**
- **VanA:** Resistant to vancomycin + teicoplanin (most common)
- **VanB:** Resistant to vancomycin, susceptible to teicoplanin
- **VanC:** Low-level vancomycin resistance (*E. gallinarum*, *E. casseliflavus*)

### **Daptomycin Dosing:**
- **Bacteremia/uncomplicated:** 8-10 mg/kg IV daily
- **Endocarditis:** 10-12 mg/kg IV daily (higher doses needed)
- **Monitor CPK weekly** (myopathy risk)

### **Linezolid Considerations:**
- **Bacteriostatic** (not ideal for endocarditis)
- **Adverse effects:** Thrombocytopenia, peripheral neuropathy, optic neuritis (prolonged use >2-4 weeks)
- **Monitor:** CBC weekly

### **Clinical Pearls:**
- ***E. faecalis*:** Ampicillin (if susceptible)
- ***E. faecium*:** Vancomycin (if susceptible), often VRE
- **VRE:** Daptomycin (8-12 mg/kg) OR linezolid (600mg q12h)
- **All enterococci resistant to cephalosporins**
- **VRE UTI:** Nitrofurantoin or fosfomycin (if cystitis)
- **Endocarditis:** Ampicillin + gentamicin (*E. faecalis*), high-dose daptomycin (VRE)

## Sources

- [IDSA: Enterococcal Infections Guidelines 2024]
- [ESCMID: VRE Management 2023]

## Media

N/A
